Skip to main content

Table 1 Patient and treatment characteristics

From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts

 

NO IPI (10 pts)

RT POST IPI (15 pts)

RT CONC IPI (20 pts)

RT PRE IPI (18 pts)

TOTAL (63 pts)

Sex

M

7

5

9

13

34

F

3

10

11

5

29

Age

Years

Median

64

62

55

63

60

Range

40–77

29–81

28–80

32–80

28–81

ECOG PS

0

8

14

17

14

53

1

2

1

3

4

10

RPA

Class I

0

0

1

3

4

Class II

10

15

19

15

59

DS-GPA

1

0

0

0

0

0

2

1

3

3

0

7

3

4

6

7

10

27

4

5

6

10

8

29

Melanoma site

Cutaneous

8

14

18

17

57

Mucosal

1

1

1

0

3

Unknown

1

0

0

1

2

Ocular

0

0

1

0

1

Time between diagnosis and BMs

Months

     

Median

34

37

23

34

34

Range

0–192

0–240

0–228

3–240

0–240

Extracranial disease

Yes

6

23

6

14

49

No

5

1

1

7

14

LDH pre-RT

Normal

4

9

11

9

33

High

4

5

7

6

22

NA

2

1

2

3

8

BRAF status

Mutated

8

5

7

9

29

Wild tipe

2

10

13

8

33

NA

   

1

1

Neurological symptoms

Asymptomatic

5

15

14

14

48

Symptomatic

5

0

6

4

15

Steroid treatment pre-RT

Yes

5

5

7

9

26

No

4

8

13

9

34

NA

1

2

–

–

3

Number of BMs treated

 

16

34

38

39

127

Lesion size

Median (mm)

9

9

8

8

8

Range (mm)

2–30

3–36

2–42

3–37

2–42

0–2 (cm)

13

28

33

31

105

> 2–< 3 (cm)

3

3

3

7

16

> 3 (cm)

0

2

2

1

5

NA

–

1

–

–

1

Radiation Treatment

SRS (dose range 10–24 Gy)

11

20

21

21

75

SRT (dose range 18–24 Gy)

4

4

6

10

24

Treatments before CK SRS/SRT

SRS

0

1

0

0

1

WBRT

2

2

0

1

5

Surgery

5

0

0

1

6

Treatments after CK SRS/SRT

SRS/SRT*

3#

7

7

8

25

WBRT

0

4

4

7

15

Surgery

1

0

0

1

2